Karuna Therapeutics, Inc. (NASDAQ:KRTX) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET

Company Participants

Alexis Smith - Senior Director of Investor Relations

Bill Meury - President and Chief Executive Officer

Troy Ignelzi - Chief Financial Officer

Andrew Miller - Founder and Chief Operating Officer

Conference Call Participants

Paul Matteis - Stifel

Nick Lenard - JPMorgan

Jason Gerberry - BofA Securities

Neena Bitritto-Garg - Citi

Laura Chico - Wedbush Securities

Jay Olson - Oppenheimer

David Amsellem - Piper Sandler

Yatin Suneja - Guggenheim Securities

Myles Minter - William Blair

Jason Butler - JMP Securities

Joseph Spak - RBC Capital Markets

Rudy Li - SVB Securities

Operator

Welcome to the Karuna Therapeutics First Quarter 2023 Financial Results Conference Call. All participants are in a listen-only mode. Please note this call is being recorded.

And I will now turn the call over to Alexis Smith, Senior Director of Investor Relations.

Alexis Smith

Thank you. Good morning, everyone, and thank you for joining our First Quarter 2023 Financial Results Conference Call. I'm joined on the call today by Bill Meury, President and Chief Executive Officer; and Troy Ignelzi, Chief Financial Officer, who will begin our call with prepared remarks as well as Andrew Miller, Founder and Chief Operating Officer; and Will Kane, Chief Commercial Officer, who will join Bill and Troy for the Q&A portion of our call.

Before we begin, I encourage everyone to visit the Investors page of our website at investors.karunatx.com to find our press release and presentation related to today's call.

Forward-looking statements related to our product development, regulatory and commercialization plans or research activities and financial outlook may be presented during this call. Please refer to today's press release and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements.

And now I'll hand it over to Bill.

Bill Meury

Thanks, Alexis, and good morning, everyone. In the beginning of this year, we outlined three strategic and operational priorities. The first is to build the core, which means maximizing the value of KarXT through our continued development efforts, submitting the NDA in the third quarter, securing FDA approval and successfully launching KarXT in 2024. The second is to expand our pipeline organically and inorganically. And the third is to scale the company and build the operational capabilities needed to support our transition to an integrated R&D and commercial organization.